Health Care & Life Sciences » Pharmaceuticals | NeuroVive Pharmaceutical AB

NeuroVive Pharmaceutical AB | Cash Flow

Fiscal year is January-December. All values SEK Thousands.
2013
2014
2015
2016
2017
2018
Net Income before Extraordinaries
22,346.00
45,254.00
91,466.00
72,110.00
71,088.00
73,360
Depreciation, Depletion & Amortization
147.00
441.00
1,200.00
1,121.00
1,595.00
238
Other Funds
233.00
260.00
28,953.00
21,455.00
10,873.00
4,867
Funds from Operations
21,966.00
44,553.00
61,313.00
49,534.00
58,620.00
68,255
Changes in Working Capital
2,876.00
920.00
5,907.00
7,843.00
496.00
4,426
Net Operating Cash Flow
19,090.00
43,633.00
67,220.00
57,377.00
58,124.00
63,829
Capital Expenditures
11,684.00
23,429.00
23,445.00
18,291.00
4,244.00
Sale of Fixed Assets & Businesses
-
-
-
-
114.00
Net Investing Cash Flow
11,684.00
23,429.00
23,445.00
25,135.00
15,165.00
Net Financing Cash Flow
33,595.00
76,599.00
138,406.00
77,332.00
9,031.00
Net Change in Cash
2,815.00
9,706.00
46,964.00
3,411.00
64,259.00
Free Cash Flow
19,158.00
43,811.00
67,465.00
57,516.00
58,164.00
Net Assets from Acquisitions
-
-
-
-
11,035.00
Change in Capital Stock
33,595.00
76,599.00
138,406.00
77,332.00
9,031.00
Exchange Rate Effect
6.00
169.00
777.00
1,769.00
1.00
Other Uses
-
-
-
6,844.00
-

About NeuroVive Pharmaceutical AB

View Profile
Address
Medicon Village
Lund SN 223 81
Sweden
Employees -
Website http://www.neurovive.com
Updated 07/08/2019
NeuroVive Pharmaceutical AB engages in the research and development of pharmaceuticals that protect mitochondria from death post acute traumatic injury. The company was founded by Eskil Elmer on February 1, 2000 and is headquartered in Lund, Sweden. .

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.